Evommune, Inc. (EVMN)
| Market Cap | 291.10M -49.8% |
| Revenue (ttm) | n/a +85.7% |
| Net Income | -113.07M |
| EPS | -3.59 |
| Shares Out | 41.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 549,398 |
| Open | 7.10 |
| Previous Close | 7.24 |
| Day's Range | 6.96 - 7.24 |
| 52-Week Range | 4.94 - 33.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 21.89 (+210.94%) |
| Earnings Date | Nov 12, 2026 |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Financial Performance
In 2025, Evommune's revenue was $13.00 million, an increase of 85.71% compared to the previous year's $7.00 million. Losses were -$68.87 million, 0.82% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for EVMN stock is "Buy." The 12-month stock price target is $21.89, which is an increase of 210.94% from the latest price.
News
Evommune Transcript: Jefferies Global Healthcare Conference
The pipeline spans EVO301 in atopic dermatitis and ulcerative colitis, an MRGPRX2 migraine inhibitor, and oral VAV1 and TLR7/8 programs, with multiple 2027–28 catalysts. $290M cash is expected to fund operations through H2 2029.
Evommune price target lowered to $23 from $26 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Evommune (EVMN) to $23 from $26 and keeps an Overweight rating on the shares.
Evommune reports Q3 EPS (85c), consensus (86c)
Reports Q3 revenue $0 vs $10M last year. The Company did not generate any revenue for the three and nine months ended September 30, 2026, compared to revenue of $10M…
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Earnings release: Q3 2026
Evommune released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Evommune Quarterly report: Q3 2026
Evommune has published its Q3 2026 quarterly earnings report on November 12, 2026.
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on November 12, 2026.
Evommune Transcript: Stifel 2026 Healthcare Conference 2026
The portfolio's next milestones include EVO301 phase II studies in atopic dermatitis and ulcerative colitis, plus 2027 clinical data for EVO646 and the newly licensed VAV1 degrader. EVO756 migraine data are targeted for Q3 2027.
Evommune to Present at Upcoming Investor Conferences
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Transcript: Investor update
EVO570’s Hinova license and $30M private placement support phase I and progression into RA phase II, with runway expected into H2 2029. Phase I data are expected mid-2027; RA phase II is planned for H2 2027.
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune prices 4.97M shares of common stock at $6.04 in private placement
Evommune (EVMN) announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in…
Evommune Announces $30 Million Private Placement
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
PALO ALTO, Calif. & NEW YORK & CHENGDU, China--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic infla...
Evommune Slides: Company presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Evommune initiated with a Neutral at UBS
UBS analyst Alice Nettleton initiated coverage of Evommune (EVMN) with a Neutral rating and $8 price target Following the positive Phase 2a data, UBS views EVO301 as a credible emerging…
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on October 8, 2026.
Evommune presents Phase 2a PoC data on EVO301 at EADV Congress
Evommune (EVMN) shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis during a late-breaking oral presentation at the European A...
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Revised summary: The company advances a diversified pipeline with two co-lead assets: an IL-18 biologic for atopic dermatitis (strong Phase IIa, moving to IIb) and an oral MRGPRX2 inhibitor in Phase IIb for migraine. Other programs include a TLR7/8 inhibitor and STAT6 degrader. Financially robust, it leverages AI and adapts to industry trends.
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Evommune price target lowered to $23 from $28 at Clear Street
Clear Street lowered the firm’s price target on Evommune (EVMN) to $23 from $28 and keeps a Buy rating on the shares. The firm has updated its model after yesterday’s…
Evommune price target lowered to $18 from $32 at Raymond James
Raymond James lowered the firm’s price target on Evommune (EVMN) to $18 from $32 and keeps an Outperform rating on the shares. Evommune’s EVO756 AD failure, following the CSU miss,…
Evommune price target lowered to $22 from $28 at Leerink
Leerink lowered the firm’s price target on Evommune (EVMN) to $22 from $28 and keeps an Outperform rating on the shares. The company announced negative results from the Phase 2b…